Literature DB >> 23614295

Polyunsaturated fatty acids inhibit melanoma cell growth in vitro.

Alicja Zajdel1, Adam Wilczok, Ewa Chodurek, Arkadiusz Gruchlik, Zofia Dzierzewicz.   

Abstract

Human malignant melanoma is a highly aggressive and incurable cancer due to intrinsic resistance to apoptosis and reprogramming proliferation and survival pathways during progression. Numerous studies, including our own, linked arachidonic acid (AA, 20:4 n-6), eicosapentaenoic acid (EPA, 20:5 n-3), and docosahexaenoic acid (DHA, 22:6 n-3) supplementation to induction of apoptosis and decreased proliferation of various cancer cells. The cytotoxic effects result from lipid peroxidation and formation of reactive oxygen species (ROS), which modify proteins and nucleic acids. DNA damage by ROS causes mutations and genomic instability, leading to uncontrolled proliferation or cell death. In the present work, four human melanoma cell lines differing in origin, doubling time, metastatic potential, and melanin content (A375, A2058, G361, and C32) were exposed to AA, EPA or DHA added into culture media in the concentrations ranging from 0 (control) to 100 mM. After 24 h incubation cytotoxicity of the analyzed acids was determined with TOX-2 (In Vitro Toxicology Assay Kit XTT Based, TOX-2, Sigma) test. The oxidative protein modifications were measured using Aldehyde Site (DNA and Protein) Detection Kit (Cayman). All the acids tested showed marked inhibition of cell proliferation. The observed effects were statistically significant and depended on the concentration. Decrease of proliferation, associated by oxidative protein and DNA damage (measured as aldehyde sites in cells), was observed for EPA and DHA (50 mM and 100 mM) in A375, A2058, and G361 cells. In case of C32 cell line, which is amelanotic melanoma, EPA and DHA inhibited cell proliferation at 100 mM only. The effect of DHA was more pronounced. AA did not show its antiproliferative action in this cell line. The obtained results suggest that antiproliferative effects of the fatty acids in cultured human melanoma cells depend on the type of acid, its concentration and may be diverse when different melanoma cell lines are used.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614295

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  6 in total

1.  Effect of fatty acids on melanogenesis and tumor cell growth in melanoma cells.

Authors:  Hidetoshi Yamada; Mayuka Hakozaki; Aiko Uemura; Tetsuro Yamashita
Journal:  J Lipid Res       Date:  2019-07-25       Impact factor: 5.922

2.  Lipid emulsions differentially affect LPS-induced acute monocytes inflammation: in vitro effects on membrane remodeling and cell viability.

Authors:  Julie Boisramé-Helms; Xavier Delabranche; Andrey Klymchenko; Jocelyne Drai; Emilie Blond; Fatiha Zobairi; Yves Mely; Michel Hasselmann; Florence Toti; Ferhat Meziani
Journal:  Lipids       Date:  2014-07-20       Impact factor: 1.880

3.  An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis.

Authors:  Jieping Li; Chih-Yu Chen; Makoto Arita; Kuijin Kim; Xiangyong Li; Hongman Zhang; Jing X Kang
Journal:  Carcinogenesis       Date:  2018-12-13       Impact factor: 4.944

4.  The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.

Authors:  Yuanqin Yin; Chengguang Sui; Fandong Meng; Ping Ma; Youhong Jiang
Journal:  Lipids Health Dis       Date:  2017-05-03       Impact factor: 3.876

5.  Oxidized unsaturated fatty acids induce apoptotic cell death in cultured cells.

Authors:  Katsuya Iuchi; Mika Ema; Moe Suzuki; Chikako Yokoyama; Hisashi Hisatomi
Journal:  Mol Med Rep       Date:  2019-02-05       Impact factor: 2.952

6.  Study of HSA interactions with arachidonic acid using spectroscopic methods revealing molecular dynamics of HSA-AA interactions.

Authors:  Fereshte Mahdizade Valojerdi; Alireza Farasat; Hanifeh Shariatifar; Nematollah Gheibi
Journal:  Biomed Rep       Date:  2019-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.